Compare Adaptive Biotechnologies Corp (ADPT) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Anheuser-Busch Inbev SA — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Anheuser-Busch Inbev SA trades at $79.97 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 39.4× Adaptive Biotechnologies Corp's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BUD | |
|---|---|---|
Market Cap | $4.04B | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $86.48 |
52-Week Low | $12.30 | $57.93 |
Enterprise Value | $4.10B | $223.42B |
Dividend Yield | — | 1.67% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
